KEEP BUT DO NOT DISPLAY

Rosiglitazone: FDA Keeps It and the Europeans Yank It! The European Medicines Agency has recommended that rosiglitazone (Avandia) and all medications containing the drug be taken off the market. The FDA says rosiglitazone can stay, but requiring a risk evaluation and mitigation strategy (REMS) program with additional measures to ensure …

EASD: Novel DPP-4 Drug Works in Renal Impairment: The novel diabetes drug linagliptin (proposed trade name Ondero) may find a niche in treating patients with kidney problems. In a phase III study of patients who couldn’t take metformin because of the drug’s GI side effects or renal impairment, linagliptin effectively …

EASD: Lixisenatide Shows Potential: Lixisenatide monotherapy significantly improves glycemic control with a pronounced postprandial effect in patients with Type 2 diabetes, and is safe and well tolerated, according to a phase 3 trial. Lixisenatide is a new potent and selective once-daily GLP-1 receptor agonist in development for the treatment of …

Merck expands Merck Helps, their free-of-charge vaccines and medicine program to individuals and families who earn up to 400% of the federal poverty level. To learn how your patients can benefit visit www.merckhelps.com.

Immune System Genes Contribute to Type 1 Diabetes: A new study found a link between immune system genes and the risk of Type 1 diabetes. Using a genome-wide association study, the researchers found that a certain group of genes that react in response to viral infections were present in both …

Use of Diabetes Pills Up, Insulin Use Down: The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60% in 1997 to 77% in 2007, a 28% increase, according to the latest “News and Numbers” from the Agency for Healthcare Research and …

Once-weekly Exenatide vs. Sitagliptin or Pioglitazone: Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did. After 26 weeks, exenatide lowered the mean HbA1c level significantly more than either sitagliptin or pioglitazone (–1.5% vs. –0.9% and –1.2%). Patients who received exenatide also lost significantly more weight than …

Light and Moderate Physical Activity Reduce the Risk of Early Death by 19%: A new study by researchers has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduce the risk of early death. The study combined the results from the largest studies …

Dietary Habits of African-Americans Are Similar, Diabetes or Not: African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites. Researchers looking for differences in the eating habits of African Americans based on whether or not they …

D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development: D-Tagatose, first in class, to treat diabetes could be the next new drug approved for diabetes and for the treatment of hypertriglyceridemia levels, pending results of the NEET trial. The effect on triglycerides is a secondary endpoint of the …